文献速递角膜与眼表疾病

意大利伦巴第地区COVID-19患者眼表SARS-CoV-2检测研究

SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该横断面研究于2020年4月9日至5月5日在意大利伦巴第瓦雷泽的ASST Sette-Laghi医院重症监护室开展,对91例住院COVID-19患者及17名健康志愿者行结膜拭子rRT-PCR检测。结果显示57.1%(95%CI 46.3%-67.5%)的COVID-19患者眼表检出SARS-CoV-2 RNA,但病毒载量双眼间差异大;41例亚组中结膜与鼻咽拭子阳性一致率为63.0%(95%CI 41.0%-81.0%),且17例鼻咽拭子阴性者中10例结膜拭子阳性。结论认为眼表可检出病毒RNA但感染性未确定,结膜拭子或可作为补充诊断检测。

要点

  • 57.1%的COVID-19住院患者眼表可检出SARS-CoV-2 RNA。
  • 结膜与鼻咽拭子阳性一致率63.0%,部分鼻咽阴性者结膜阳性。
  • 眼表病毒RNA的感染性未能确定,结膜拭子可考虑作为补充诊断。

核心结论

  • 在COVID-19患者中,较大比例的眼表可检出SARS-CoV-2 RNA,但该物质的感染性无法确定。
  • 部分患者结膜拭子阳性而鼻咽拭子阴性,结膜拭子可考虑作为补充诊断检测。

研究设计与样本

  • 横断面研究,于2020年4月9日至5月5日在意大利伦巴第瓦雷泽的ASST Sette-Laghi医院重症监护室开展。
  • 共纳入108名参与者(平均[SD]年龄58.7[14.2]岁;55女53男),包括91例经鼻咽拭子rRT-PCR和影像学临床诊断的COVID-19住院患者及17名无COVID-19症状的健康志愿者。
  • 通过结膜拭子采集样本,采用rRT-PCR assay检测SARS-CoV-2。

主要发现

  • 91例COVID-19患者中52例眼表检出SARS-CoV-2(57.1%;95%CI 46.3%-67.5%),双眼平均病毒载量差异大。
  • 41例亚组中,结膜与鼻咽拭子检测间隔2天内时阳性一致率为63.0%(95%CI 41.0%-81.0%)。
  • 该17例鼻咽拭子阴性患者中,10例结膜拭子阳性。

关键数值与推荐

  • 91例COVID-19患者眼表SARS-CoV-2检出率为57.1%(95%CI 46.3%-67.5%)。
  • 41例亚组结膜与鼻咽拭子阳性一致率为63.0%(95%CI 41.0%-81.0%),检测间隔在2天内。
  • 17例鼻咽拭子阴性患者中10例结膜拭子阳性。

临床怎么用

  • 对COVID-19患者可考虑采用结膜拭子rRT-PCR作为补充诊断检测,尤其鼻咽拭子阴性时。
  • 结膜拭子检测结果需结合鼻咽拭子和临床情况综合判断,眼表病毒RNA感染性尚未确定。

局限性

  • 眼表检出SARS-CoV-2 RNA的感染性无法确定。
  • 结膜与鼻咽拭子一致率分析仅基于41例亚组,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Since February 2020, coronavirus disease 2019 (COVID-19) has spread rapidly all over the world, with an epidemiological cluster in Lombardy, Italy. The viral communicability may be mediated by various body fluids, but insufficient information is available on the presence of the virus in human tears. OBJECTIVES: To investigate the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tears collected from patients with COVID-19 by means of real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) assay and to assess the association of virus presence with concomitant clinical conditions. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study conducted between April 9 and May 5, 2020. The setting was intensive care units at Azienda Socio-Sanitaria Territoriale (ASST) Sette-Laghi Hospital, University of Insubria, in Varese, Lombardy, Italy. A conjunctival swab was performed in 91 patients hospitalized for COVID-19, which was clinically diagnosed by rRT-PCR assay on nasopharyngeal swabs and by radiological imaging. Conjunctival swabs from 17 additional healthy volunteer participants with no symptoms of COVID-19 were examined to evaluate the availability and applicability of the conjunctival swab test. EXPOSURE: SARS-CoV-2 detection by means of rRT-PCR assay performed on the collected samples obtained by conjunctival swabs. MAIN OUTCOMES AND MEASURES: Conjunctival swab and nasopharyngeal swab results are reported, as well as demographic and clinical data. RESULTS: A total of 108 participants (mean [SD] age, 58.7 [14.2] years; 55 female and 53 male) were tested for SARS-CoV-2 using rRT-PCR assay, including 91 patients hospitalized with COVID-19 and 17 were healthy volunteers. SARS-CoV-2 was found on the ocular surface in 52 of 91 patients with COVID-19 (57.1%; 95% CI, 46.3%-67.5%), with a wide variability in the mean viral load from both eyes. Among a subset of 41 patients, concordance of 63.0% (95% CI, 41.0%-81.0%) was found between positive conjunctival and nasopharyngeal swab test results when performed within 2 days of each other. In 17 of these patients, nasopharyngeal swab results were negative for SARS-CoV-2. In 10 of these 17 patients, conjunctival swab results were positive for the virus. CONCLUSIONS AND RELEVANCE: In this study, SARS-CoV-2 RNA was found on the ocular surface in a large part of this cohort of patients with COVID-19, although the infectivity of this material could not be determined. Because patients may have positive test results with a conjunctival swab and negative results with a nasopharyngeal swab, use of the slightly invasive conjunctival swab may be considered as a supplementary diagnostic test.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Azzolini C, Donati S, Premi E, et al. SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy. JAMA Ophthalmol. 2021. PMID: 33662099. doi:10.1001/jamaophthalmol.2020.5464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。